Neurologist with Special Interest in
Movement Disorders

 Julius B.-M. Anang (MD, PhD, FRCPC, DCH&TM)

Office Telephone: (204) 925-9539    Fax Number:  1-855-461-1857

Availability: Appointment by Consultation/Referral Only

Neuromdclinic Link: https://neuromdclinic.com/our-doctors/

Medical School:

Johannes Gutenberg University Mainz, Germany

Neurology residency:

University of Saskatchewan, University of Manitoba, Canada

Movement Disorders Fellowship:

McGill University, Montreal, Canada

Others:

Postgraduate Studies in Internal Medicine: Charite Berlin, Germany

Diploma in Community Health and Tropical Medicine: University of Heidelberg, Germany

Languages:

English, French and German (consultations in any of these languages)

Clinical Interest:

Diagnosis and management of movement disorders:

• Parkinson disease and Parkinson-like disorders
  • Including advanced therapies such as continuous levodopa-carbidopa intestinal gel infusion therapy (DUODOPA)
• Tremor, dystonia, ataxia, tics, myoclonus, chorea
• Botulinum toxin injection therapy for movement disorders
• Dyskinesia and drug-induced movement disorders etc.
• Sleep related movement disorders
• Selected areas of general neurology

Research Interests:

Tremor management and rehabilitation

Diagnosis and management of complications of Parkinson disease

Peer-reviewed Publications:

1. Wright N, Alhindi A, Millikin C, Modirrousta M, Udow S, Borys A, Anang J, Hobson DE and Ko JH. Elevated caudate connectivity in cognitively normal Parkinson’s disease patients. Sci Rep 10, 17978 (2020).
Doi: https://doi.org/10.1038/s41598-020-75008-6

2. Anang, J. Levodopa-Carbidopa-Related Rash in Parkinson’s Disease: A Case Series. Can J Neurol Sci. 2018 Sep;45(5):588 -589. Doi: https://doi.org/10.1017/cjn.2018.58

3. Dawson B, Fereshtehnejad SM, Anang JBM, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB. Office-Based Screening for Dementia in Parkinson DiseaseThe Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts. JAMA Neurol. Published online March 26, 2018. Doi: http://dx.doi.org/10.1001/jamaneurol.2018.0254

4. Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, Appel-Cresswell S, Moro A, Borys A, Hobson D and Lang AE. Caffeine as Symptomatic Treatment for Parkinson’s Disease (Café-PD): A Randomized Trial. Neurology 2017 Oct 24;89(17):1795-1803. Doi: http://dx.doi.org/10.1212/WNL.0000000000004568

5. Anang JBM, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB. Dementia Predictors in Parkinson Disease: A Validation Study. J Parkinson’s Disease 2017; 7(1) 159 -162. Doi: http://dx.doi.org/10.3233/JPD-160925 

6. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. JAMA Neurol. 2015 Aug;72(8):863-73. Doi: http://dx.doi.org/10.1001/jamaneurol.2015.0703

7. Romenets SR, Anang J, Fereshtehnejad SM, Pelletier A, Postuma RB. Tango for treatment of motor and non-motor manifestations in Parkinson’s disease: A Randomized control study. Complementary Therapies in Medicine 2015; 23:175-184. Doi:http://dx.doi.org/10.1016/j.ctim.2015.01.015

8. Kawada T, Anang JB, Postuma R. Predictors of dementia in Parkinson disease: A prospective cohort study. Author response. Neurology 2015; 84(12): 1285-6. Doi: http://dx.doi.org/10.1212/WNL.0000000000001408

9. Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB. Predictors of dementia in Parkinson disease: A prospective cohort study. Neurology 2014; 83(14): 1253-60. Doi:  http://dx.doi.org/10.1212/WNL.0000000000000842

10. Anang J and Tellez-Zenteno JF (2012). Single Unprovoked Seizure: Wait Time to Full Medical Assessment, Does it Matter? Neurol. Bull. 2012; 4: 1 – 11. Download article here

Published Manuscripts and books:

1. 2019 Compendium of Basic and Clinical Research in Parkinson’s Disease. Highlights from the 2019 International Congress of Parkinson’s Disease and Movement Disorders. A Canadian Perspective. Reviewed by the Schulich School of Medicine and Dentistry, University of Western Ontario, Canada. Co-author. Click here to view

2. Compendium of Basic and Clinical Research in Advanced Parkinson’s Disease. Highlights from the 2018 International Congress of Parkinson’s Disease and Movement Disorders. A Canadian Perspective. Reviewed by the Schulich School of Medicine and Dentistry, University of Western Ontario, Canada. Co-author. Click to download or here

3. Compendium of Basic and Clinical Research in Advanced Parkinson’s Disease. Highlights from the International Congress of Parkinson’s Disease and Movement Disorders 2017. A Canadian Perspective. Reviewed by the Schulich School of Medicine and Dentistry, University of Western Ontario, Canada.Co-author.

4 .Basic and Clinical Research Update in Parkinson’s disease. Highlights from the 4th World Parkinson Congress 2016: A Canadian Perspective. September 20-23, Portland, Oregon, USA. Reviewed by the Schulich School of Medicine and Dentistry, University of Western Ontario, Canada. Co-author.

5. Parkinson’s Disease. An Introductory Guide (patient education).

            Ron Postuma and Julius Anang. Published in 2017. Download here